Overview

A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.

Status:
Terminated

Trial end date:
2009-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to understand safety and tolerability of the drug GSK1018921 after 14 days of dosing in healthy volunteers and then in patient volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Glycine
Midazolam